OncoMatch/Clinical Trials/NCT05503667
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Is NCT05503667 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Furmonertinib and Bevacizumab for lung adenocarcinoma stage iii.
Treatment: Furmonertinib · Bevacizumab — To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitive mutation
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
The patient has undergone any systemic anti-cancer treatment for NSCLC, including cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.
Lab requirements
Blood counts
Other major organs shall function well (liver, kidney, blood system, etc.)
Kidney function
Other major organs shall function well (liver, kidney, blood system, etc.)
Liver function
Other major organs shall function well (liver, kidney, blood system, etc.)
Cardiac function
Good lung function that could tolerate surgical treatment; exclusion of congestive heart failure (≥ Grade II NYHA), cardiac infarction (6 months before enrollment), severe arrhythmia
Good lung function that could tolerate surgical treatment; Other major organs shall function well (liver, kidney, blood system, etc.); exclusion of congestive heart failure (≥ Grade II NYHA), cardiac infarction (6 months before enrollment), severe arrhythmia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05503667 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR sensitive mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages